Eli Lilly’s $7 billion move to buy Kelonia is not an outlier. It is the third multibillion-dollar in vivo gene therapy acquisition in half a year, underscoring a rush among pharma giants to secure platforms that work inside the body rather than through traditional cell handling. The velocity is striking: Kelonia, founded just four years ago with a $50 million Series A, now represents one of the largest private biotech exits in the past decade. For investors, the scale and timing point to a market where strategic acquirers are willing to pay extraordinary premiums to get ahead of a therapeutic shift they see as inevitable.
Viewed alongside recent activity, a clear pattern emerges. Moderna’s $2.4 billion purchase of Orna in February, Janssen’s $2.1 billion acquisition of Capstan in June, and AstraZeneca’s $1.5 billion deal for Orbital in October all target early in vivo platforms. These companies share two traits: minimal clinical maturity and the ability to reprogram immune cells directly inside the patient. Buyers are paying for speed, optionality, and the chance to lock down proprietary delivery systems before competitors do. The premium valuations reflect a strategic calculation that the first wave of scalable in vivo platforms could reshape large therapeutic categories and reduce manufacturing complexity.
The signal for investors is direct. In vivo platforms are now proven acquisition magnets commanding valuations rarely seen at pre-commercial stages. Timing is becoming a differentiator, with buyers stepping in far earlier than in previous gene therapy cycles. For allocators, early exposure to similar platforms offers asymmetric exit potential as pharma continues to acquire ahead of clinical proof. The next set of targets will likely emerge from the same technical niche—companies positioned to deliver genetic instructions in the body rather than in the lab.
